Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | Tivantinib | MET | RTK | 0.27263 | -0.3523 | 0.4830 | 0.2060 | 2.4177 | 0.34098 | 0.99571 |
MCF7 | Buparlisib | pan PI3K | PI3K/mTOR | 0.18746 | -0.2690 | 0.5035 | 0.1162 | 0.8936 | 0.34198 | 0.99189 |
Hs 578T | Ipatasertib | AKT | PI3K/mTOR | 4.5924 | 0.4423 | 0.2458 | 0.0093 | 0.5006 | 0.34659 | 0.98155 |
HCC1143 | Tivantinib | MET | RTK | 0.27789 | -0.3122 | 0.4977 | 0.1369 | 1.9433 | 0.35725 | 0.99341 |
HCC38 | Trametinib | MEK | MAPK/nRTK | 0.22023 | 0.1854 | 0.2076 | 0.0234 | 0.6910 | 0.35783 | 0.98881 |
BT-549 | Trametinib | MEK | MAPK/nRTK | 5.2409 | 0.5983 | 0.1292 | 0.0152 | 0.5005 | 0.36186 | 0.97942 |
HCC1937 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.5349 | 0.1565 | 0.0058 | 1.0014 | 0.36202 | 0.97156 |
CAMA-1 | Tivantinib | MET | RTK | 0.27573 | -0.5655 | 0.5259 | 0.2061 | 2.2178 | 0.36921 | 0.99228 |
MDA-MB-468 | Tivantinib | MET | RTK | 0.30706 | -0.4549 | 0.4903 | 0.2341 | 2.9835 | 0.37002 | 0.99499 |
T47D | Tivantinib | MET | RTK | 0.3478 | -0.1544 | 0.3824 | 0.1267 | 3.7033 | 0.37139 | 0.99567 |
CAL-120 | Tivantinib | MET | RTK | 0.25132 | -0.2562 | 0.4649 | 0.1572 | 1.1267 | 0.37355 | 0.99876 |
Hs 578T | Bleomycin | Radiation | Misc | 0.25197 | -0.1966 | 0.4462 | 0.2094 | 0.9580 | 0.37819 | 0.99872 |
MDA-MB-436 | Etoposide | Topo II | Chemotherapy | 0.26013 | -0.1571 | 0.4348 | 0.0454 | 0.9014 | 0.38084 | 0.99169 |
SUM159PT | Bleomycin | Radiation | Misc | 0.28119 | -0.0577 | 0.4191 | 0.1680 | 0.7700 | 0.38984 | 0.99881 |
HCC38 | Tivantinib | MET | RTK | 0.30919 | -0.2702 | 0.4367 | 0.1297 | 1.8013 | 0.39141 | 0.99767 |
HCC1419 | Tivantinib | MET | RTK | 0.47955 | 0.1634 | 0.2618 | 0.0408 | 2.6512 | 0.40663 | 0.98985 |
SUM159PT | Palbociclib | CDK4/6 | Cell cycle | 1.1058 | 0.3876 | 0.1990 | -0.0006 | 0.6326 | 0.40763 | 0.99661 |
MDA-MB-468 | Neratinib | EGFR/HER2 | RTK | 0.15781 | -0.3825 | 0.3861 | 0.1513 | 0.8303 | 0.41607 | 0.99579 |
MDA-MB-453 | Etoposide | Topo II | Chemotherapy | 0.38265 | -0.0601 | 0.3658 | 0.0418 | 1.5864 | 0.41689 | 0.99692 |
PDX1258 | Etoposide | Topo II | Chemotherapy | 0.31701 | -0.1807 | 0.3942 | 0.1360 | 1.0906 | 0.41876 | 0.99346 |
HCC70 | Etoposide | Topo II | Chemotherapy | 0.36498 | -0.1518 | 0.4535 | 0.0513 | 2.1004 | 0.41879 | 0.96872 |
Hs 578T | Tivantinib | MET | RTK | 0.33668 | -0.3204 | 0.4411 | 0.2071 | 2.0560 | 0.42597 | 0.99878 |
MDA-MB-231 | Tivantinib | MET | RTK | 0.41694 | -0.0845 | 0.3330 | 0.1029 | 2.2640 | 0.43275 | 0.99134 |
MDA-MB-134-VI | Ceritinib | ALK | RTK | 0.13159 | -0.9992 | 0.6654 | 0.1723 | 0.9173 | 0.43587 | 0.98922 |
MDA-MB-436 | Tivantinib | MET | RTK | 0.3675 | -0.2711 | 0.4215 | 0.0897 | 2.2220 | 0.44342 | 0.99833 |